Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)

被引：6
|
作者：
Hong, D. S. [1 ]
Bang, Y-J. [2 ]
Barlesi, F. [3 ]
Durm, G. A. [4 ]
Falchook, G. S. [5 ]
Govindan, R. [6 ]
Dy, G. K. [7 ]
Park, K. [8 ]
Strickler, J. H. [9 ]
Burns, T. F. [10 ]
Kim, J. [11 ]
Ang, A. [12 ]
Lipford, J. R. [13 ]
Ngarmchamnanrith, G.
Anderson, A. [12 ]
Li, B. T. [14 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Phase & Clin Trials Program, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[2] Seoul Natl Univ, Coll Med, Dept Internal Med Med Oncol, Seoul, South Korea
[3] Aix Marseille Univ, CNRS, INSERM, CRCM,AP HP, Gustave Roussy Canc Campus, Villejuif, France
[4] Indiana Univ, Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN USA
[5] HealthONE, Sarah Cannon Res Inst, Dept Med Oncol, Denver, CO USA
[6] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA
[7] Roswell Pk Comprehens Canc Ctr, Dept Med, Buffalo, NY USA
[8] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[9] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[10] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Dept Med,Div Hematol Oncol, Pittsburgh, PA USA
[11] Amgen Inc, Biostat, Thousand Oaks, CA 91320 USA
[12] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA
[13] Amgen Inc, Clin Dev, Thousand Oaks, CA 91320 USA
[14] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1571
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1257O
引用
收藏
页码：S812 / S812
页数：1
相关论文
共 50 条
  • [21] EVALUATION OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG-CANCER (NSCLC)
    FOEMMEL, RS
    ALEXANDER, NA
    HIRSHAUT, Y
    KATOPODIS, N
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 182 - 182
  • [22] Comorbidity in clinical trial patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Kosov, Maxim
    Kumar, Akhil
    Belotserkovskiy, Maxim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Prognostic significance of aneuploidy in non-small cell lung cancer (NSCLC) patients (pts).
    Dziadziuszko, R
    Wegrzynowicz, E
    Kardas, I
    Limon, J
    Jassem, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 695S - 695S
  • [24] The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).
    Paz-Ares, Luis G.
    Garon, Edward B.
    Ardizzoni, Andrea
    Barlesi, Fabrice
    Cho, Byoung Chul
    Castro, Gilberto
    De Marchi, Pedro
    Felip, Enriqueta
    Goto, Yasushi
    Greystoke, Alastair
    Lu, Shun
    Lim, Darren Wan Teck
    Papadimitrakopoulou, Vassiliki
    Reck, Martin
    Solomon, Benjamin J.
    Spigel, David R.
    Tan, Daniel Shao-Weng
    Thomas, Michael
    Yang, James Chih-Hsin
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC)
    Bagley, Stephen
    Kothari, Shawn
    Aggarwal, Charu
    Bauml, Joshua
    Alley, Evan
    Evans, Tracey
    Kosteva, John
    Ciunci, Christine
    Thompson, Jeffrey
    Stonehouse-Lee, Susan
    Sherry, Victoria
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    Dilullo, Gloria
    Cohen, Roger
    Vachani, Anil
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1289 - S1289
  • [26] Survival data and toxicity profile in advanced non-small cell lung cancer (NSCLC) patients (PTS) treated within or outside controlled clinical trials.
    Vavala, Tiziana
    Rovere, Giulia
    Rapetti, Simonetta
    Capelletto, Enrica
    Longo, Marina
    Levra, Matteo Giaj
    Crida, Benedetta
    Novello, Silvia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Clinical predictive factors in real world setting in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Callejo, A.
    Marmolejo, D.
    Iranzo, P.
    Assaf, J. D.
    Pardo, N.
    Navarro, A.
    Martinez-Marti, A.
    Cedres, S.
    Diaz Mejia, N. M.
    Carbonell, C.
    Amat, R.
    Frigola, J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S766 - S766
  • [28] Real-world evidence and clinical characteristics in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI)
    Iranzo, P.
    Callejo, A.
    Marmolejo, D.
    Assaf, J. D.
    Pardo, N.
    Navarro, A.
    Martinez-Marti, A.
    Cedres, S.
    Diaz Mejia, N. M.
    Carbonell, C.
    Amat, R.
    Frigola, J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S767 - S767
  • [29] Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib
    Gadgeel, Shirish
    Chen, Wei
    Piotrowska, Zofia
    Goldman, Jonathan W.
    Wakelee, Heather
    Camidge, D. Ross
    Varga, Andrea
    Yu, Helena
    Papadimitrakopoulou, Vassiliki
    Nea, Joel
    Soria, Jean-Charles
    Wozniak, Antoinette
    Riely, Gregory
    Narayanan, Vignesh
    Mendenhal, Melody
    Sequist, Lecia
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1263 - S1263
  • [30] Clinical and Plasma Biomarkers for Disease Control with Nivolumab Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Daher, Sameh
    Lawrence, Yaacov
    Dudnik, Elizabeth
    Hanovich, Ekaterina
    Urban, Damien
    Peled, Nir
    Navon, Rossie
    Leibowitz-Amit, Raya
    Hammerman, Ariel
    Battat, Erez
    Bar, Jair
    Onn, Amir
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1307 - S1307
12345